RxDoctor Payments Data

Alok Banga, MD

Child & Adolescent Psychiatry · Elk Grove, CANPI 1083807531

Payments from drug & device makers

$318in general payments, 2019–2025

Across 13 payments — averaging $24.44 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Johnson & Johnson$163
  • ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$47
  • Otsuka America Pharmaceutical, Inc.$44
  • Supernus Pharmaceuticals, Inc.$35
  • AbbVie$28

What the payments were for

  • Food & beverage$27185%
  • Education$4715%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
21
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$318 in reported general payments places this provider in the 60th percentile of 434 child & adolescent psychiatry providers in California.

See all child & adolescent psychiatry providers in California

Medicare billing

Part B allowed, 2024
$232,131
Medicare patients
221
Services billed
2,449

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
IngrezzaValbenazine Tosylate18$207,249
SpravatoEsketamine Hcl48$72,306
Invega SustennaPaliperidone Palmitate18$71,927
VraylarCariprazine Hcl12$32,707
CaplytaLumateperone Tosylate15$26,913
TrintellixVortioxetine Hydrobromide11$11,484
Lurasidone Hcl11$9,428
VyvanseLisdexamfetamine Dimesylate14$7,073
Bupropion XlBupropion Hcl133$4,402
Vilazodone Hcl23$3,989
Quetiapine Fumarate167$3,148
Aripiprazole62$3,063
Divalproex Sodium46$2,803
Duloxetine Hcl58$2,722
Clozapine34$2,287

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Johnson & JohnsonSpravato, Invega Sustenna$163$144,23266 claims
AbbVieVraylar$28$32,70712 claims
ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)Caplyta$47$26,91315 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 434 child & adolescent psychiatry providers in California.

Other child & adolescent psychiatry in Elk Grove

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →